This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ResMed Sees Potential in SDB Market, Eyes Global Growth
by Zacks Equity Research
On Jul 6, we issued an updated research report on San Diego, CA-based ResMed, Inc. (RMD).
ResMed (RMD) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of ResMed Inc. (RMD) scaled a new 52-week high of $79.22 on Jun 19, eventually closing a bit lower at $78.91.
Why Is ResMed (RMD) Down 3.8% Since the Last Earnings Report?
by Zacks Equity Research
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ResMed (RMD) Beats Q3 Earnings, Misses Sales Estimates
by Zacks Equity Research
ResMed Inc. (RMD) announced third-quarter fiscal 2017 adjusted earnings per share (EPS) of 71 cents, up 2.8% from the prior-year quarter level.
Medical Product Stocks' Earnings on Apr 27: ZBH, RMD & More
by Zacks Equity Research
Let's take a look at the major Medical products stocks slated to release their Jan-Mar 2017 quarter's reports on Apr 27.
ResMed (RMD) Q3 Earnings: Disappointment in the Cards?
by Zacks Equity Research
ResMed Inc. (RMD) is slated to report third-quarter fiscal 2017 results, after market close on Apr 27.
ResMed's Study Results for Central Sleep Apnea Hold Promise
by Zacks Equity Research
ResMed Inc. (RMD) recently sponsored a study which shows potential treatment of obstructive sleep apnea (OSA) in patients with untreated central sleep apnea (CSA).
Align Partners Zfx GmbH to Expand iTero Scanner Business
by Zacks Equity Research
Align Technology Inc. (ALGN) announced a non-exclusive agreement with digital prosthetic solutions maker, Zfx GmbH on iTero Element intraoral scanners.
VWR Corp Acquires EPL Archives, Improves Customer Service
by Zacks Equity Research
VWR Corporation (VWR) recently acquired the international biorepository services organization, EPL Archives, Inc.
PetMed Express' New Order Sales Disappoint, Competition Rife
by Zacks Equity Research
On Mar 23, we issued an updated research report on Pompano Beach, FL-based PetMed Express, Inc. (PETS).
Zacks Industry Outlook Highlights: Quidel, OraSure Technologies, ResMed, Inogen and Masimo
by Zacks Equity Research
Zacks Industry Outlook Highlights: Quidel, OraSure Technologies, ResMed, Inogen and Masimo
Walgreen Boots Buyout of Rite Aid Delayed, Other Woes Remain
by Zacks Equity Research
On Mar 24, we issued an updated research report on Illinois-based leading pharmacy-led, health and wellbeing enterprise, Walgreens Boots Alliance, Inc. (WBA).
Medtronic's (MDT) CoreValve Evolut Pro Receives FDA Approval
by Zacks Equity Research
Medical device major Medtronic plc (MDT) recently announced that it has received the FDA approval for its CoreValve Evolut PRO valve.
Hologic Completes Cynosure Buyout, Boosts Core Business
by Zacks Equity Research
Hologic, Inc. (HOLX) recently announced the completion of it earlier declared acquisition of marketer of aesthetic treatment systems, Cynosure, Inc.
Align's iTero Hits 1 Billion Mark, Boosts Scanner Business
by Zacks Equity Research
Align Technology Inc. (ALGN) has recently revealed that more than one million scans have been submitted using its iTero Element scanner in less than two years.
Genomic Health's Cancer Test Business Strong, Expenses High
by Zacks Equity Research
On Mar 20, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX), a leading global cancer company with a focus on advanced molecular diagnostics.
Integer (ITGR) Amends Term B Loan to Lower Interest Rate
by Zacks Equity Research
Integer Holdings Corporation (ITGR) announced that it has completed an amendment to its senior secured credit facilities to lower the interest rate on its Term B Loan Facility.
Genomic Health's Breast Recurrence Test Data Encouraging
by Zacks Equity Research
Genomic Health, Inc. (GHDX), a leading molecular diagnostics company, recently presented results from 15 Oncotype DX Breast Recurrence Score studies.
Medtronic's Positive 2-Year SURTAVI Data Boosts Corevalve
by Zacks Equity Research
Medtronic plc (MDT) has released the first-ever clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial.
Abbott Laboratories' MitraClip Outcome Positive for DMR
by Zacks Equity Research
Abbott Laboratories (ABT) recently presented one-year positive outcomes from the study of the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the U.S.
Thermo Fisher Poised on Innovation, Global Growth Amid Woes
by Zacks Equity Research
On Mar 17, 2017, we issued an updated research report on Thermo Fisher Scientific Inc. (TMO).
CVS Health Launches Reduced Rx for Affordable Medication
by Zacks Equity Research
CVS Health Corporation (CVS), a leading name in pharmacy benefit and retail pharmacy, recently announced the launch of a prescription savings program-Reduced Rx.
Medtronic's Melody TPV Wins FDA for Less-Invasive Treatment
by Zacks Equity Research
Medtronic plc (MDT) recently won FDA approval for Melody Transcatheter Pulmonary Valve for implantation in patients whose surgical bioprosthetic pulmonary heart valves have failed.
Align Technology Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Share price of San Jose, CA-based Align Technology, Inc. (ALGN) reached a new 52-week high of $110.87 on Mar 15, eventually closing a bit lower at $110.31.
ResMed (RMD) Up 3.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.